ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
-0.30%
Brent Oil
81.295
0.00%
Bitcoin
67,783.06
0.45%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Atara Biotherapeutics Inc (ATRA)

  7. Atara Biotherapeutics Inc (ATRA) Noticias

ATRA

Atara Biotherapeutics (ATRA)

Atara Biotherapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ATRA
FechaHoraFuenteTítuloSímboloCompañía
29/05/202415:01Business WireAtara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
22/05/202417:18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:ATRAAtara Biotherapeutics Inc
20/05/202419:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
20/05/202408:25Business WireAtara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDANASDAQ:ATRAAtara Biotherapeutics Inc
16/05/202420:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATRAAtara Biotherapeutics Inc
10/05/202415:30Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202415:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATRAAtara Biotherapeutics Inc
09/05/202415:01Business WireAtara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
03/05/202415:01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
28/03/202407:30Business WireAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational ProgressNASDAQ:ATRAAtara Biotherapeutics Inc
29/02/202408:05Business WireAtara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T TherapyNASDAQ:ATRAAtara Biotherapeutics Inc
28/02/202415:30Business WireAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
14/02/202408:00Business WireAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus NephritisNASDAQ:ATRAAtara Biotherapeutics Inc
01/02/202401:25PR Newswire (US)Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet OncologyNASDAQ:ATRAAtara Biotherapeutics Inc
09/01/202415:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATRAAtara Biotherapeutics Inc
08/01/202408:00Business WireAtara Biotherapeutics Announces $15 Million Registered Direct OfferingNASDAQ:ATRAAtara Biotherapeutics Inc
08/01/202407:00Business WireAtara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
04/01/202415:01Business WireAtara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
03/01/202415:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATRAAtara Biotherapeutics Inc
20/12/202315:01Business WireAtara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre LaboratoriesNASDAQ:ATRAAtara Biotherapeutics Inc
11/12/202311:00Business WireAtara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual MeetingNASDAQ:ATRAAtara Biotherapeutics Inc
01/12/202315:01Business WireAtara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ATRAAtara Biotherapeutics Inc
29/11/202317:05Business WireAtara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023NASDAQ:ATRAAtara Biotherapeutics Inc
22/11/202315:01Business WireAtara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
17/11/202315:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATRAAtara Biotherapeutics Inc
13/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATRAAtara Biotherapeutics Inc
10/11/202315:01Business WireAtara Biotherapeutics To Participate at the Stifel Healthcare ConferenceNASDAQ:ATRAAtara Biotherapeutics Inc
08/11/202316:35Business WireAtara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple SclerosisNASDAQ:ATRAAtara Biotherapeutics Inc
01/11/202316:25Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATRAAtara Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATRA

Su Consulta Reciente

NASDAQ
AKLA
NYSE
GIX.U
GigCapital2
EU
FR001400NJ99
Societe Generale SFH SA ...
COIN
EGGEUR
NASDAQ
AAWXYXX
JPMorgan Chase Financial...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados